Absence of triadin, a protein of the calcium release complex, is responsible for cardiac arrhythmia with sudden death in human by Roux-Buisson, Nathalie et al.
Absence of triadin, a protein of the calcium release
complex, is responsible for cardiac arrhythmia
with sudden death in human
Nathalie Roux-Buisson1,2,3,4,{, Marine Cacheux1,4,{, Anne Fourest-Lieuvin1,4,5,
Jeremy Fauconnier6,7,8,9, Julie Brocard1,4, Isabelle Denjoy10, Philippe Durand11,
Pascale Guicheney12,13, Florence Kyndt14,15,16, Antoine Leenhardt10, Herve ´ Le Marec14,16,17,
Vincent Lucet18, Philippe Mabo19, Vincent Probst14,16,17, Nicole Monnier1,2, Pierre F. Ray2,3,4,
Elodie Santoni2, Pauline Tre ´meaux2, Alain Lacampagne6,7,8,9, Julien Faure ´1,2,4, Joe ¨l Lunardi1,2,4
and Isabelle Marty1,4,∗
1INSERM U836, Grenoble Institut des Neurosciences, Equipe Muscle et Pathologies, Grenoble, France,
2CHRU de
Grenoble, Hopital Michallon, Biochimie et Ge ´ne ´tique Mole ´culaire, Grenoble, France,
3Laboratoire AGIM, FRE 3405
CNRS-UJF, Equipe Ge ´ne ´tique Infertilite ´ et The ´rapeutique, La Tronche, France,
4Universite ´ Joseph Fourier, Grenoble,
France,
5Institut de Recherches en Technologies et Sciences pour le Vivant, Direction des Sciences du Vivant, CEA
Grenoble, France,
6INSERM U1046, Montpellier, France,
7Universite ´ Montpellier 1, Montpellier, France,
8Universite ´
Montpellier 2, Montpellier, France,
9CHU de Montpellier, Montpellier, France,
10Centre de Re ´fe ´rence Maladies
Cardiaques He ´re ´ditaires, Universite ´ Paris Diderot, Sorbonne Paris Cite ´, Service de Cardiologie, AP-HP, Ho ˆpital
Bichat, Paris, France,
11Service de Re ´animation Pe ´diatrique et Me ´decine Ne ´onatale, Ho ˆpital du Kremlin Bice ˆtre, AP-
HP, France,
12INSERM, UMR S 956, Paris, France and
13Universite ´ Pierre et Marie Curie-Paris 6, IFR14, Paris,
France,
14INSERM, UMR915, l’institut du thorax, Nantes, France,
15CHU Nantes, Service de Ge ´ne ´tique Me ´dicale,
France,
16CHU Nantes, l’institut du thorax, Nantes, France,
17Universite ´ de Nantes, Nantes, France,
18Unite ´ de
rythmologie et de cardio-pe ´diatrie, Cha ˆteau des Co ˆtes, Les loges en Josas, France and
19Service de Cardiologie et
Maladies Vasculaires, CHU Rennes, Rennes, France
Received January 20, 2012; Revised and Accepted March 8, 2012
Catecholaminergic polymorphic ventricular tachycardia (CPVT) is an inherited arrhythmogenic disease so far
related to mutations in the cardiac ryanodine receptor (RYR2) or the cardiac calsequestrin (CASQ2) genes.
Because mutations in RYR2 or in CASQ2 are not retrieved in all CPVT cases, we searched for mutations in
the physiological protein partners of RyR2 and CSQ2 in a large cohort of CPVT patients with no detected mu-
tation in these two genes. Based on a candidate gene approach, we focused our investigations on triadin and
junctin, two proteins that link RyR2 and CSQ2. Mutations in the triadin (TRDN)a n di nt h ej u n c t i n( ASPH)
genes were searched in a cohort of 97 CPVT patients. We identiﬁed three mutations in triadin which cosegre-
gated with the disease on a recessive mode of transmission in two families, but no mutation was found in
junctin. Two TRDN mutations, a 4 bp deletion and a nonsense mutation, resulted in premature stop
codons; the third mutation, a p.T59R missense mutation, was further studied. Expression of the p.T59R
mutant in COS-7 cells resulted in intracellular retention and degradation of the mutant protein. This was con-
ﬁrmed after in vivo expression of the mutant triadin in triadin knock-out mice by viral transduction. In this
work, we identiﬁed TRDN as a new gene responsible for an autosomal recessive form of CPVT. The mutations
†These two authors contributed equally to this work.
∗To whom correspondence should be addressed at: GIN, Inserm U836, Eq Muscle et Pathologies, Bat EJ Safra, Chemin Fortune ´ Ferrini, 38700 La
Tronche, France. Tel: +33 456520571; Fax: +33 456520572; Email: isabelle.marty@ujf-grenoble.fr
# The Author 2012. Published by Oxford University Press.
This is an Open Access article distributed under the terms of the Creative Commons Attribution Non-Commercial License (http://creativecommons.org/
licenses/by-nc/2.5), which permits unrestricted non-commercial use, distribution, and reproduction in any medium, provided the original work is prop-
erly cited.
Human Molecular Genetics, 2012, Vol. 21, No. 12 2759–2767
doi:10.1093/hmg/dds104
Advance Access published on March 14, 2012identiﬁed in the two families lead to the absence of the protein, thereby demonstrating the importance of tria-
din for the normal function of the cardiac calcium release complex in humans.
INTRODUCTION
Catecholaminergic polymorphic ventricular tachycardia
(CPVT; MIM #604772), a potentially fatal cardiac arrhythmia,
is a genetic disorder characterized by stress-induced syncope
and/or sudden death in juveniles and young adults in the
absence of structural alteration of the heart (1,2). The two
genes currently associated with CPVT, ryanodine receptor
(RYR2) and calsequestrin (CASQ2), encode proteins respon-
sible for sarcoplamic reticulum (SR) calcium release during
cardiac muscle contraction. They belong to the macromolecu-
lar calcium release complex (CRC), composed mainly of fol-
lowing proteins: the SR calcium release channel ryanodine
receptor (RyR2); the CSQ2, which acts as a calcium buffer
inside the SR; triadin and junctin, two proteins that have
been implicated in anchoring CSQ2 to RyR2, at the terminal
cisternae of SR (3,4). Mutations have been identiﬁed in
RYR2 and CASQ2 in only 70% of the patients affected by
CPVT, indicating that other genes are involved in this
disease. Therefore, the genes encoding triadin or junctin, the
two linkers between RyR2 and CSQ2, naturally appeared as
interesting candidate genes for CPVT.
Triadinisamultiproteinfamilyarisingfromthealternativespli-
cingofasingleTRDNgene(MIM#603283)localizedonChr6and
containing 41exons (5). Two isoforms,Trisk95 and Trisk51, are
exclusively expressed in skeletal muscle. A third one, Trisk 32
(also called CT1), is expressed mainly in cardiac muscle (6).
Two triadin knock-out (KO) mouse models have been developed,
presenting with cardiac arrhythmia and skeletal muscle weakness
(7–9). Therefore, the presence of triadin seems essential for
normal cardiac and skeletal muscle function.
Junctin, a 26 kDa protein expressed both in skeletal and
cardiac muscle (10) (MIM #600582), is an alternative splice
product of the aspartyl-b-hydroxylase gene on Chr8 [ASPH,
(11)]. Two junctin isoforms are expressed in human cardiac
muscle (12). Junctin is involved in regulation of the calcium
homeostasis, and deletion of junctin in a mouse model
results in fatal arrhythmia (13).
This study presents the molecular investigations performed
in a large panel of well-characterized CPVT patients in which
mutations in RYR2 and CASQ2 genes had been excluded.
Pathophysiological and clinical consequences of the mutations
identiﬁed in the TRDN gene in two families have been
analyzed and will be discussed.
RESULTS
Clinical phenotype
The proband of family 1 (ind II:1, Fig. 1) originated from
French West Indies. He was a 2-year-old boy who experienced
syncope followed by cardiac arrest after a shock while playing
with his 7-year-old brother. Resting electrocardiogram follow-
ing cardiac resuscitation showed numerous polymorphic or bi-
directional ventricular extra beats and runs of polymorphic
ventricular tachycardia (Supplementary Material, Fig. S1a).
He died in the hospital 3 weeks following the initial cardiac
arrest after a severe post-anoxic coma. There was no positive
family history. The parents and the brother of the proband
were considered healthy as their resting ECG, Holter record-
ings and exercise stress tests did not show any abnormality.
The proband of Family 2 (ind II:2, Fig. 1) originated from
Western France. He was a 26-year-old man who presented
with recurrent syncopes at exercise since the infancy.
Resting ECG was normal with no prolongation of the QT
interval. Exercise testing showed numerous bidirectional ven-
tricular extra beats (Supplementary Material, Fig. S1b). The
patient also presented with proximal muscle weakness.
CPVT was also diagnosed in his dizygotic twin-brother (ind
II:3) after clinical examination. They were both treated by
nadolol 40 mg/day, a non-selective b-blocker. Clinical evalu-
ation, Holter recording and exercise testing did not show any
abnormalities among other family members investigated (ind
II:1 and III:1).
Genetic analysis
Molecular analysis of the TRDN gene in Family 1 identiﬁed a
c.del53_56ACAG homozygous deletion in exon 2. This dele-
tion of four nucleotides resulted in a frameshift in the amino
acid sequence from amino acid 18 leading to a premature ter-
mination codon (PTC) at position 31, designed p.D18Afs∗13
according to the nomenclature proposed by the Human
Genome Variation Society (14) (http://www.hgvs.org/m
utnomen/recs-prot.html). This mutation was identiﬁed at a
heterozygous state in the three unaffected relatives tested
(Fig. 1A). Haplotype analyses were performed in the
family using polymorphic markers ﬂanking the TRDN
gene (cen-D6S1712-D6S979-TRDN-D6S1639-D6S408-tel)
and were suggestive of a remote common ancestor.
Molecular analysis in Family 2 revealed that the two
affected individuals II:2 and II:3 were compound heterozy-
gous for a c.176C.G missense mutation in exon 2 that led
to the substitution of a threonine by an arginyl residue at pos-
ition 59 (p.T59R) and a c.613C.T nonsense mutation in exon
8 that introduced a PTC at position 205 in the amino acid
sequence (p.Q205∗). Unaffected individuals tested carried
one (ind III:1) or no variant (ind II:1) (Fig. 1A).
In both the families, the phenotype–genotype analysis was
in favor of a recessive form of CVPT. The frameshift deletion
c.del53_56delACAG; p.D18Afs∗13 inducing a stop codon in
position 31 would result in deletion of the major part of the
protein, and the production of a short cytosolic peptide as
the stop was located before the transmembrane helix
(Fig. 1B). The nonsense variation c.613C.T; p.Q205∗ gener-
ated a stop codon in position 205, just before the KEKE motif
(domain composed of repetition of Lys and Glu) (15) located
in position 210–224 responsible for interaction of Trisk 32
with RyR2 and CSQ2 (16,17). These two mutations resulting
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either to an absence of protein synthesis via nonsense-
mediated mRNA decay (18), or to the production of a non-
functional protein. The p.T59R variation affected a well-
conserved position in Trisk 32 and resulted in the introduction
of a positively charged amino acid in the transmembrane
domain of the protein. The deleterious effect of the substitu-
tion within the transmembrane domain of this conserved threo-
nine at position 59 by an arginine was less predictable and was
thus further studied.
Localization of the mutant p.T59R in a model cell line
The effect of the p.T59R mutation on the behavior of Trisk 32
was ﬁrst studied by expression in the non-muscle COS-7 cell
line, and analysis of the localization of the wild-type (WT)
(T32) or mutant protein (T32-T59R) by confocal microscopy.
When expressed in COS-7 cells, the WT Trisk 32 was loca-
lized in the plasma membrane of 83% of the cells (Fig. 2A,
panel PM) and in the endoplasmic reticulum for the remaining
17% of the cells (Fig. 2A, panel ER) (n ¼ 500 cells). The
p.T59R mutation induced the exclusive localization of Trisk
32 in an intracellular compartment (100%, n ¼ 500 cells),
identiﬁed as endoplasmic reticulum by co-localization with
the endoplasmic reticulum (ER) resident protein calnexin
(Supplementary Material, Fig. S2a). This observation was con-
ﬁrmed by differential immunoﬂuorescent labeling before and
after permeabilization of the cells (Fig. 2B). Whereas Trisk
32 was labeled both on intact and permeabilized cells, con-
ﬁrming its plasma membrane localization, the mutant Trisk
32-T59R was accessible only after permeabilization thus indi-
cating an intracellular retention. This intracellular retention
was also conﬁrmed by biotinylation of cell surface proteins
(Supplementary Material, Fig. S2b).
Stability of the mutant Trisk 32-T59R in a model cell line
As a lower level of expression of Trisk 32-T59R was observed
in COS-7 cells compared with the WT Trisk 32, the stability of
the mutant protein was evaluated. After transfection in COS-7
cells, Trisk 32 and Trisk 32-T59R appeared as a triple band of
centered on 37 kDa, due to post-translational modiﬁcation
(glycosylation), as observed previously (19,20). Transfected
cells were incubated with cycloheximide (CHX), a protein
synthesis inhibitor, and the amounts of Trisk 32 and Trisk
32-T59R were analyzed by quantitative western blotting
after various incubation times. The relative amount of Trisk
32-T59R decreased faster than the relative amount of Trisk
32 (Fig. 3A), indicating a faster turnover of the mutant
Trisk 32-T59R compared with the WT Trisk 32. This sug-
gested that the abnormal localization observed for Trisk
32-T59R could result in protein instability and degradation.
This degradation was further analyzed by proteasome inhib-
ition by MG132. Proteasome inhibition did not increase the
total amount of the WT Trisk 32, but it raised the amount of
the mutant Trisk 32-T59R by 148% (Fig. 3B). This showed
that Trisk 32-T59R was targeted for proteasome-mediated
degradation. Altogether, results in COS-7 cells showed that
mutant Trisk 32-T59R was unable to exit ER after synthesis
and was prone to degradation most probably via the
proteasomal pathway.
Stability and localization of the mutant Trisk 32-T59R
after in vivo expression
The behavior of the mutant Trisk 32-T59R was further studied
after re-expression in the triadin KO mouse. The triadin KO
mouse, a mouse line devoid of any triadin isoform, has been
previously shown to present both cardiac arrhythmia (8) and
muscle weakness (9). Viruses [AAV2/9, which preferentially
target the heart in adult mice (21,22)] were developed to
induce in vivo expression of the WT and mutant Trisk 32 pro-
teins in the heart of triadin KO mice. One month after systemic
injection of the viral vectors, the cardiomyocytes were isolated
and characterized by different methodological approaches.
The mRNA expression levels studied by semi-quantitative
reverse transcription polymerase chain reaction (RT–PCR)
of the WT Trisk 32 and the mutant Trisk 32-T59R were
similar (Fig. 4A), showing that the mutation did not affect
transcript stability. In contrast, the determination of the
Figure 1. Triadin mutations in two CPVT families. (A) Pedigrees of the two CPVT families. Filled squares indicated affected individuals and half ﬁlled symbols
individuals heterozygous for a mutation. The proband in each Family is indicated by the black arrow. The genotype for each individual concerning the identiﬁed
mutation is indicated as follow: ‘+’ in the presence of the mutation and ‘2’ in the absence of the mutation. (B) Membrane topology of cardiac isoform of triadin,
Trisk 32, in the sarcoplasmic reticulum membrane with the localization of the three identiﬁed mutations. The ‘KEKE’ region is the interaction domain with RyR2
and CSQ2. Trisk 32 has a C-terminal speciﬁc region from amino acid 264–286.
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cardiomyocytes homogenates (Fig. 4B) showed that no mutant
protein could be detected in any of the six transduced mice,
whereas the transduced WT Trisk 32 was detected in all the
mice (Fig. 4B and Supplementary Material, Fig. S3). This
difference in expression was conﬁrmedby immunoﬂuorescence
labeling on ﬁxed cardiomyocytes (Fig. 5). In WT cardiomyo-
cytes (Fig. 5A–C), Trisk 32 presented a typical dyad labeling,
a row of dots co-localized with RyR2. In the triadin KO cardi-
omyocytes (Fig. 5D–F), Trisk 32 labeling was absent and
RyR2 labeling was not modiﬁed. After transduction of Trisk
32orTrisk32-T59RinthetriadinKOmice,onlythetransduced
Figure 2. Trisk 32 and Trisk 32-T59R cell localizations are different. (A) Trisk 32-T59R is located only at the endoplasmic reticulum, whereas Trisk 32 is mainly
at the plasma membrane. WT Trisk 32 (T32) and mutant Trisk 32-T59R (T32–T59R) were transfected in COS-7 cells, and their localization analyzed by im-
munoﬂuorescent labeling. Typical Trisk 32 labeling at the plasma membrane (PM) or in the ER are shown. Bar: 20 mm. The histogram shows the percentage of
transfected cells exhibiting PM (closed square) or ER (open square) labeling, for a total of 500 transfected cells from three different experiments. ∗∗∗P , 0.001,
Fisher’s test comparison of T32- vs. T32–T59R-transfected cells. (B) Immunoﬂuorescent labeling on intact or permeabilized cells shows intracellular retention
of Trisk 32-T59R. Transfected cells were ﬁxed without permeabilization and stained with an antibody directed against the C-terminal end of Trisk 32, which is
extracellular when the protein is in the plasma membrane (left panels, ‘intact’). Afterwards, cells were permeabilized and stained with an antibody directed
against the N-terminal end of Trisk 32, which is cytosolic when the protein is in the plasma membrane or in the reticulum membrane (right panels, ‘permea-
bilized’). Bar: 20 mm.
Figure 3. The mutant protein Trisk 32-T59R is degraded faster, via the proteasome. (A) Trisk 32-T59R is degraded faster in the course of protein synthesis
inhibition. WT Trisk 32 (T32) and mutant Trisk 32-T59R (T32-T59R) were ﬁrst transfected in COS-7 cells. Transfected cells were then incubated with cyclo-
heximine (CHX) to block protein synthesis for the indicated time. Cells were collected and analyzed by quantitative western blot with speciﬁc antibodies to
evaluate the amount of protein. The curves show the quantiﬁcation from four experiments of the amount of each protein (T32 -†- and T32-T59R -A-) compared
with its initial amount. ∗∗∗P , 0.001, F-test comparison of the two curves, based on decay and plateau parameters. (B) Inhibition of the proteasome raises the
amount of the mutant protein Trisk 32-T59R. Twenty hours after transfection, the cells were incubated during 6 h with either dimethyl sulfoxide (DMSO) alone
for controls (lanes ‘2’) or 50 mM MG132 to block proteasome (lanes ‘+’). The cells were then collected and analyzed by quantitative western blot with speciﬁc
antibodies. The top panel shows a typical western blot, the bottom histogram (B DMSO; A MG132) is a quantiﬁcation (mean+SEM) from three experiments.
∗P , 0.05, Mann and Whitney test comparison of DMSO- vs. MG132-treated cells.
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where it perfectly colocalized with RyR2 (Fig. 5G–I) while
the transduced mutant Trisk 32-T59R was not detectable
(Fig. 5J–L). This suggests although the mRNA of Trisk
32-T59R is expressed in the cardiomyocytes of the mice, the
protein is absent.
DISCUSSION
CPVT is a life-threatening inheritable disease that predisposes
young individuals with normal cardiac structure to cardiac
arrest. Pre-symptomatic genetic screening is of major
importance for CPVT families, since life-saving preventive
treatments are available. Therefore, the identiﬁcation of causa-
tive mutations constitutes a major issue for CPVT families. Up
to now, two genes have been involved in this disease. They
encode proteins which constitute the core of the cardiac
CRC: RyR2 in the dominant forms of CPVT and CSQ2 in
the recessive forms. However, almost one-third of the patients
remained without an identiﬁed molecular defect. In the present
work, we searched for mutations in other genes in a panel
of 97 CVPT patients without mutations in the RYR2 and
CASQ2 genes. We focused our screening on triadin and
junctin which are the physiological partners of RyR2 and
CSQ2 in the CRC. No mutation was identiﬁed in junctin,
whereas three mutations were identiﬁed in triadin. The charac-
terization of the physiopathological mechanisms is of upper-
most importance for a better understanding of the disease
and for the development of new therapies, as the current ther-
apies are not fully satisfying (1). Along this line, we searched
for the functional consequences of the TRDN mutations. Two
of these mutations resulted in a premature stop codon, and the
corresponding proteins are most probably not produced as a
consequence of NMD (18). Thus, we focused our investigation
on the third mutation, the missense p.T59R.
To study the consequences of this mutation, we analyzed
the localization and the stability of the mutant protein in
COS-7 cells and in cardiomyocytes. All the experiments we
performed, either in transfected COS-7 cells or in cardiomyo-
cytes from triadin KO mice transduced in vivo, showed that
the p.T59R mutation resulted in instability of the protein,
leading to its degradation. It would be interesting in this
context to assay the ability of blockers of ER quality control
or of molecular chaperones to restore the folding of Trisk
32-T59R and its correct targeting instead of its degradation,
as done for a-sarcoglycan mutations in Limb Girdle Muscular
Dystrophy type 2D (23,24). The likely absence of the protein
as a result of the mutation in patient’s heart could only be
further conﬁrmed by western blot on a cardiac biopsy,
which was not available. As the two other mutations
(p.D18Afs∗13, homozygous mutation in Family 1 and
p.Q205∗, compound heterozygous mutation associated to
p.T59R in Family 2) most likely resulted in the absence of
the protein, all the affected patients in this study can be con-
sidered natural triadin KO cases. The severe CPVT phenotype
observed in these patients thus highlights the role of triadin in
the regulation of the calcium release during cardiac contrac-
tion. In addition, the identiﬁed mutations mapped to a region
of the TRDN gene which is common to all triadin isoforms, in-
cluding the skeletal muscle Trisk 95 and Trisk 51. Thus, these
three mutations would also lead to an absence of triadin in the
skeletal muscle. This would give a possible explanation for the
associated muscle weakness that was clinically observed in in-
dividual II:2 in Family 2. The affected patient in Family 1 died
so young (2 years) that muscle weakness could not have been
detected, but it could be envisaged that CPVT related to triadin
mutation systematically affect both cardiac and skeletal
muscle. Therefore, when a CPVT patient presents also with
a moderate muscle weakness, screening of the TRDN gene
should be performed at ﬁrst. In this context, the triadin KO
mouse is a good model to study the consequences of triadin
deletion in human, as it presents with the same disease
Figure 4. Stability analyses of transcripts and proteins after in vivo expression
in triadin KO mice. (A) The mutant transcript is present at similar levels as the
WT one. Messenger RNAs were puriﬁed from isolated cardiomyocytes of
transduced mice. After reverse transcription, the cDNAs were either directly
used or diluted 10 or 100 times before the PCR ampliﬁcation of Trisk 32
(T32) and GAPDH. PCR products for Trisk 32 and GAPDH ampliﬁcation
were expected, respectively, at 250 and 136 bp. The PCR primers for
GAPDH were designed to co-amplify possible contaminating genomic DNA
as a 220 bp fragment, which was not observed. (B) The mutant protein
Trisk 32-T59R was not detectable. Western blot analysis of 100 mg of cardi-
omyocytes homogenates from control WT mouse, with mouse-speciﬁc anti-
Trisk 32 antibody (ﬁrst lane), or 100 mg of cardiomyocytes from a Trisk
32-transduced mouse (second lane), or Trisk 32-T59R-transduced mouse
(third lane) with rat-speciﬁc anti-Trisk 32 antibody. Trisk 32 appears as mul-
tiple bands (2/3) centered on 37 kDa, the higher bands, the glycosylated forms
of Trisk 32, being in lower amount and visible in correlation with the intensity
of the signal, as described before (6,20).
Human Molecular Genetics, 2012, Vol. 21, No. 12 2763hallmarks: muscle weakness (9) and cardiac arrhythmia
induced by b-adrenergic stimulation (8). Different mechan-
isms have been proposed to explain the cardiac arrhythmia
resulting of RYR2 or CASQ2 mutations (2,25). Among the pos-
sible mechanisms, one is related to the dissociation of
FKBP12.6 from RyR2 in the case of RYR2 mutation, which
would result in a leaky Ca
2+ channel (26). This mechanism
could be envisaged for the triadin deletion resulting from the
mutations identiﬁed in the present study, as it has been pro-
posed in the triadin KO mouse that triadin ablation could
impair FKBP12/RyR1 interaction in skeletal muscle (27).
Such a hypothesis should nevertheless be conﬁrmed in the
heart for FKBP12.6/RyR2 interaction. Another mechanism
proposed as a result of CASQ2 mutations is a reduction in
the amount of CSQ2 or in the calcium-binding capacity of
the mutant CSQ2. Such a mechanism could also be proposed
in the case of the identiﬁed triadin mutations, as a CSQ2 re-
duction has been observed in the triadin KO mouse heart
(8). Therefore, the triadin mutations identiﬁed in the present
study and the characterization of the triadin KO mice lines
performed previously (8,9) conﬁrmed the hypothesis that
CPVT could be more generally the result of a functional
defect in the CRC (2,28). Our study clearly showed that muta-
tions in the TRDN gene are responsible for CPVT in the
human and is therefore a gene to systematically investigate
when screening familial CPVT. Nevertheless, the absence of
mutation in RYR2, CASQ2, ASPH and TRDN in the 94 remain-
ing patients of this cohort points to the limitation of the gene
candidate approach. To search for other genes that might be
involved, a large-scale screening should be performed in
Figure 5. Immunoﬂuorescent analysis of Trisk 32 in isolated cardiomyocytes. Cardiomyocytes were isolated from a WT mouse, a triadin KO mouse (KO), a
triadin KO mouse transduced with rat Trisk 32 (KO + T32) and a triadin KO mouse transduced with rat Trisk 32-T59R (KO + T32-T59R). They were labeled
with antibodies against mouse Trisk 32 and RyR (A–F) or against rat Trisk 32 and RyR (G–L). In all cardiomyocytes, RyR labeling is typical of a dyad labeling
showing aligned rows of dots, as observed in the inserts. Bar: 2 mm.
2764 Human Molecular Genetics, 2012, Vol. 21, No. 12these patients. Finally, this paper described for the ﬁrst time an
involvement of the TRDN gene in human pathology, and inter-
estingly, although this gene encodes for cardiac and muscle
triadins, the pathology is mainly a cardiac one.
MATERIALS AND METHODS
Ethics statement
Investigations of patient population reported in the paper
received a formal approval from the Regional Medical
Ethical Committee (Comite ´ de Protection des Personnes,
CHU de Saint-Etienne; France). All procedures using
animals were approved by the Institutional ethics committee
and followed the guidelines of the National Research
Council Guide for the care and use of laboratory animals.
Clinical evaluation of probands
The patient population consisted in 97 CPVT probands care-
fully characterized after clinical examination and electrocar-
diographic records. Referred to the clinical centers for
syncope with or without seizures, or cardiac arrest, they
have been diagnosed on the basis of typical polymorphic ven-
tricular arrhythmia recorded on 12-lead ECG, and after 24 h
Holter ECG and exercise stress test. Family members were
evaluated at least by resting ECG, and when possible a 24 h
ECG Holter recordings and exercise stress test were
performed.
Genetic analysis
Blood samples used for genetic evaluation were obtained after
a written informed consent was signed by patients according to
the French regulation for genetic studies. Molecular screening
of RYR2 and CASQ2 genes has been performed as described
before (29). Screening of the two junctin isoforms was per-
formed by sequencing the six exons (NM_02164.4) corre-
sponding to the longest isoform. Molecular analysis of the
TRDN gene was performed by sequencing all the exons that
encode the cardiac human isoform Trisk 32. Because of the
large number of triadin transcripts described in the cardiac
tissue originating from different species (19,30,31) without
the experimental evidences for the existence of the corre-
sponding proteins, we ﬁrst characterized the human Trisk 32
sequence both at the cDNA and at the protein level using
human cardiac tissue (Supplementary Material, Fig. S4 and
Supplementary Methods). The presence of the corresponding
protein was conﬁrmed using an antibody developed against
the speciﬁc C-terminal end of the identiﬁed sequence (Supple-
mentary Material, Fig. S4c). The sequence of human Trisk 32
identiﬁed in this study is accessible in GenBank database
under accession number JN900469. Primers sequences used
for molecular investigation of the TRDN and ASPH genes
are listed in Supplementary Material, Table S1. Family
members were screened for the mutation(s) identiﬁed in pro-
bands. A panel of 300 control chromosomes was screened
for each novel variant reported in this study.
Plasmids, viruses and antibodies
Full-length cDNA coding for rat Trisk 32 (accession number:
EMBL AJ812276), with or without c.176C.G mutation, cor-
responding to p.T59R change in the protein, was inserted into
pcDNA3.1 (Invitrogen, Cergy Pontoise, France) for cell trans-
fection, or in pZac2.1 for AAV development. The rat Trisk 32
nucleotide sequence used in this study has 84% identity with
the human sequence and 92% with the mouse sequence, and
was chosen because of the availability of efﬁcient antibodies
(20) developed in different species and necessary for the
double immunoﬂuorescent labeling. All viruses were engi-
neered and produced by the Penn Vector Core (Philadelphia,
PA, USA). Two recombinant adeno-associated viruses of
serotype 2/9, encoding respectively the WT and the mutant
T59R–Trisk 32 were used in this study: AAV-Trisk 32 and
AAV-Trisk 32-T59R. All the transgenes were under the
control of a CMV promoter.
Rabbit anti-RyR antibodies have been described previously
(32), as well as rabbit anti-peptide antibodies against the
N-terminal end of triadins (33), and anti-peptide antibodies
against the rat Trisk 32 C-terminal end (20), developed in
rabbit or guinea pig. We also used anti-peptide antibodies
against the mouse Trisk 32 (9), and an anti-RyR developed
in guinea pig by immunization with the C-terminal peptide
of RyR1, as described before (34). The rabbit polyclonal anti-
body to calnexin (SPA-860) is from Stressgen (Victoria,
Canada).
Cell culture, transfection and treatment
COS-7 cells were cultured in Dulbecco’s modiﬁed Eagle
medium supplemented with 10% fetal bovine serum and 1%
penicillin/streptomycin (Invitrogen). Cells were transfected
using Exgen 500 (Euromedex, Mundolsheim, France) for
28 h for immunoﬂuorescent labeling experiments and for
20 h for western blot analysis after CHX or MG132 treatment.
For triadin stability experiment, transfected COS-7 cells
were treated with 50 mg/ml of CHX for 0–6 h, or with
50 mM MG132 for 6 h, or with 0.2% dimethyl sulfoxide
(DMSO) for 6 h (control). Cells were then lysed with radioim-
muno precipitation assay buffer [25 mM Tris, pH 7.6, 150 mM
NaCl, 1% NP-40, 1% sodium deoxycholate, 0.1% sodium
dodecyl sulfate (SDS)], centrifuged and proteins in the super-
natant were precipitated by chloroform/methanol for further
analysis by quantitative western blot.
Immunoﬂuorescent labeling on COS-7 cells
and on cardiomyocytes
Transfected COS-7 cells were ﬁxed either 6 min in cold
methanol at 2208C, or 10 min in 4% paraformaldehyde
(PFA). For detection of Trisk 32 at the cell surface, cells
ﬁxed with PFA were incubated with a guinea pig antibody
against the C-terminus of rat Trisk 32. After permeabilization
with 0.05% saponin, cells were incubated with a rabbit
antibody against the N-terminus of rat Trisk 32 and then
with secondary antibodies against both species.
Primary cardiomyocytes were seeded 1 h on laminin-coated
glass cover slip, ﬁxed 15 min in 4% PFA, permeabilized for
Human Molecular Genetics, 2012, Vol. 21, No. 12 276530 min in phosphate buffered saline (PBS)—0.5% Triton
X-100, then saturated 1 h in PBS—0.1% Triton X-100—
0.5% bovine serum albumin—2% goat serum, and incubated
with primary antibodies.
The cells were observed under a LEICA SPE confocal
microscope.
Mice and in vivo transduction
Triadin KO mice developed on C57Bl6 background were
described previously (9). Two-month-old triadin KO male
mice (19–24 g) were anesthetized with xylazine (10 mg/g)
and ketamine (100 mg/g), and injected with 2 × 10
11 viral
genome copy diluted in 100 ml of 150 mM NaCl, by a single
injection in the tail vein.
Cardiomyocytes preparation
One month after virus injection, the hearts of transduced KO
mice of non-transduced KO mice or of WT littermate mice
were collected and cardiac ventricular myocytes were enzyma-
tically dissociated as previously reported (35). Brieﬂy, mice
were euthanized by cervical dislocation, the heart rapidly
excised and retrogradely perfused at 378C for 6–8 min with
a modiﬁed tyrode solution (in mM: NaCl 113, KCl 4.7,
KH2PO4 0.6, Na2HPO4 0.6, MgSO4 1.2, NaHCO3 12,
KHCO3 10, 4-(2-hydroxyethyl)-1-piperazineethanesulfonic
acid 10 Taurine 30, pH ¼ 7.4) containing 0.1 mg/ml liberase
(Roche, France). Isolated cardiomyocytes were then trans-
ferred to the same solution, free of enzyme, containing 1 mM
CaCl2.
RT–PCR
mRNA expression levels in transduced cardiomyocytes were
determined by semi-quantitative RT–PCR. Brieﬂy, total
RNA was extracted from isolated cardiomyocytes using
TRIzol Reagent and PureLink RNA Mini Kit (Invitrogen).
First-strand cDNA was synthesized from 500 ng of total
RNA using speciﬁc primer mixes followed by cDNA ampliﬁ-
cation. Primer sequences were as follows: rat Trisk 32:
forward, 5′-AGCCAAAGAAACTCCGAAAA-3′; reverse,
5′-TCCAGTGGC CGTATGTACTTC-3′; mouse GAPDH:
forward, 5′-CGTGCCGCCTGGAGAAAC-3′; reverse, 5′-TG
GGAGTTGCTGTTGAAGTCG-3′. Equal amounts of cDNA
were used in each reaction sample.
Western blot
Cardiomyocytes or transfected cells were homogenized by
15 s sonication at 08C in the presence of 1 mM DFP and
200 mM PMSF as proteases inhibitors. One hundred micro-
grams of cardiomyocyte homogenates were analyzed by quan-
titative western blot analysis as described previously (9), with
antibodies against rat Trisk 32 (20) or mouse Trisk 32 (9). Sec-
ondary antibodies used for western blot were labeled with
horseradish peroxydase (Jackson ImmunoResearch Laborator-
ies, Immunotech S.A.S., Marseille, France). The quantiﬁcation
was performed with a Chemidoc and the Quantity One soft-
ware (BioRad, Marnes la Coquette, France).
Statistics
Statistics were performed using either Fisher’s test (Figs 2A
and 3A) or Mann and Whitney’s test (Fig. 3B) on Prism 4.0
software (GraphPad, San Diego, CA, USA).
SUPPLEMENTARY MATERIAL
Supplementary Material is available at HMG online.
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